NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Immutep Limited IMMP
10 fiscal years on record · AUD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
AUD 10.3M
▲ 31.8% vs FY2023
EPS · FY24
AUD -0.04
Dividend / sh · FY24
—
Payout · FY24
-0%
ROE · FY24
-36.9%
Net margin · FY24
-594.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
AUD 10.3M
Revenue, FY2024 · full 10-year series below
Revenue
Net income
The company lost 595 cents on every revenue dollar this year.
Per share
AUD -0.04
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-36.9%
Return on equity, FY2024
ROE
Operating margin—
Net margin-594.6%
Return on assets-34.3%
Each AUD of equity lost 37 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit-0.0%
Consecutive raises—
Growth
−8.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.2%
−8.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
AUD 157.0M
total assets, end of FY2024
Total assetsAUD 157.0M
EquityAUD 143.6M
CashAUD 67.4M
DepositsAUD 62.3M
Current ratio11.69×
Equity funds 91% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · AUD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue AUD B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income AUD B
·
·
·
·
·
·
·
·
·
·
EBITDA AUD B
·
·
·
·
·
·
·
·
·
·
Income tax AUD B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
Net income AUD B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
EPS, diluted AUD
−0.04
−0.04
−0.04
−0.04
−0.05
−0.03
−5.29
−4.63
−0.40
−2.78
Dividend / sh AUD
·
·
·
·
·
·
·
·
·
·
Payout %
−0
−0
−0
−0
−0
−0
−0
−0
−0
·
ROE %
−36.9
−26.2
−34.6
−38.5
−56.1
−46.7
−63.4
−42.4
−35.3
·
Shares out B
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 29
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 4 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed